Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Quidel Corporation

Healthcare US QDEL

19.3USD
-0.56(2.82%)

Last update at 2026-03-10T20:00:00Z

Day Range

18.9220.13
LowHigh

52 Week Range

37.7889.11
LowHigh

Fundamentals

  • Previous Close 19.86
  • Market Cap2950.11M
  • Volume1152279
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA620.30M
  • Revenue TTM2862.70M
  • Revenue Per Share TTM42.81
  • Gross Profit TTM 1936.00M
  • Diluted EPS TTM-27.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 735.90M 900.36M 1040.32M 77.18M 63.38M
Minority interest - - - - -
Net income 548.70M 704.23M 810.29M 72.92M 74.18M
Selling general administrative 621.00M 84.25M 66.59M 52.76M 44.95M
Selling and marketing expenses - 175.32M 133.96M 111.11M 108.99M
Gross profit 1936.00M 1270.89M 1348.86M 320.81M 315.71M
Reconciled depreciation 132.50M 54.38M 49.09M 51.79M 46.27M
Ebit 843.70M 906.07M 1060.33M 52.59M 63.86M
Ebitda 1104.10M 915.62M 1064.02M 104.38M 110.13M
Depreciation and amortization 260.40M 9.56M 3.69M 51.79M 46.27M
Non operating income net other - -5.70600M -20.00700M -15.53800M -32.54500M
Operating income 843.70M 906.07M 1060.33M 52.59M 95.93M
Other operating expenses 2286.30M 782.93M 597.65M 430.51M 412.16M
Interest expense 75.70M 5.71M 9.62M 14.79M 24.28M
Tax provision 187.20M 196.13M 230.03M 4.26M -10.79900M
Interest income 1.30M - - 14.79M 24.28M
Net interest income -75.70000M -5.70600M -9.62300M -14.79000M -24.28300M
Extraordinary items - - - - -
Non recurring - -9.55700M -3.69400M -11.66700M -14.19700M
Other items - - - - -
Income tax expense 187.20M 196.13M 230.03M 4.26M -10.79900M
Total revenue 3266.00M 1698.55M 1661.67M 534.89M 522.28M
Total operating expenses 956.30M 355.27M 284.83M 216.42M 205.59M
Cost of revenue 1330.00M 427.66M 312.81M 214.09M 206.57M
Total other income expense net -107.80000M -5.70600M -20.00700M 24.59M -22.45900M
Discontinued operations - - - - -
Net income from continuing ops 548.70M 704.23M 810.29M 72.92M 74.18M
Net income applicable to common shares 548.70M 704.23M 810.29M 72.92M 74.18M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 8563.10M 8855.80M 2430.37M 1871.16M 910.87M
Intangible assets 2934.30M 3123.80M 98.66M 122.43M 148.11M
Earning assets - - - - -
Other current assets 77.00M 252.10M 4.59M 2.16M 1.89M
Total liab 3557.20M 3921.20M 501.01M 538.46M 351.05M
Total stockholder equity 5005.90M 4934.60M 1929.36M 1332.70M 559.82M
Deferred long term liab - 3.50M 36.49M 73.95M 109.38M
Other current liab 335.70M 439.80M 210.07M 239.11M 78.62M
Common stock 0.10M - 0.04M 0.04M 0.04M
Capital stock 0.10M 0.00000M 0.04M 0.04M 0.04M
Retained earnings 2187.80M 2197.90M 1649.20M 944.97M 134.68M
Other liab - 294.90M 48.58M 96.69M 127.55M
Good will 2492.00M 2476.80M 337.02M 337.03M 337.02M
Other assets - 395.80M 39.71M 158.82M 31.63M
Cash 118.90M 292.90M 802.75M 489.94M 52.77M
Cash and equivalents - - - - -
Total current liabilities 833.80M 1007.00M 323.52M 336.96M 125.89M
Current deferred revenue 36.80M 76.40M 1.92M 3.73M 1.50M
Net debt 2495.20M 2531.80M -664.15600M -381.43600M 59.52M
Short term debt 166.50M 207.50M 10.04M 7.80M 19.07M
Short long term debt 139.80M 207.50M - - 12.66M
Short long term debt total 2614.10M 2824.70M 138.59M 108.50M 112.30M
Other stockholder equity 2848.00M 2804.30M 279.77M 388.12M 425.56M
Property plant equipment - 1520.00M 349.20M 110.48M 79.76M
Total current assets 1310.50M 1575.10M 1440.31M 1142.40M 222.23M
Long term investments 7.40M 21.00M 37.85M - -
Net tangible assets - -666.00000M 1622.24M 973.95M 167.92M
Short term investments 48.40M 52.10M 25.76M - -
Net receivables 488.40M 453.90M 393.85M 529.17M 104.91M
Long term debt 2274.80M 2430.80M - - -
Inventory 577.80M 524.10M 198.76M 113.80M 58.09M
Accounts payable 294.80M 283.30M 101.49M 86.32M 26.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -30.00000M -67.60000M 0.35M -0.43100M -0.46300M
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - 1649.20M 944.97M 134.68M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 179.00M 122.70M 19.62M 13.51M 7.13M
Deferred long term asset charges - - - - 24.50M
Non current assets total 7252.60M 7280.70M 990.06M 728.76M 688.64M
Capital lease obligations 199.50M 186.40M 138.59M 108.50M 99.64M
Long term debt total - - - - 4.38M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -187.60000M -1644.20000M -63.68700M -63.32200M -27.22900M
Change to liabilities - 23.50M -23.33700M 220.19M 7.36M
Total cashflows from investing activities - -1644.20000M -319.53000M -63.32200M -27.22900M
Net borrowings - 346.20M -0.26000M -0.51100M -54.29200M
Total cash from financing activities -265.80000M 252.00M -173.17700M -130.27700M -98.28200M
Change to operating activities - -83.20000M 19.65M 15.99M 9.24M
Net income -10.10000M 548.70M 704.23M 810.29M 72.92M
Change in cash -174.00000M -508.90000M 312.81M 437.17M 9.08M
Begin period cash flow 292.90M 802.80M 489.94M 52.77M 43.70M
End period cash flow 118.90M 293.90M 802.75M 489.94M 52.77M
Total cash from operating activities 280.20M 885.30M 805.87M 629.76M 134.49M
Issuance of capital stock 11.60M 26.40M 7.55M 9.61M 14.78M
Depreciation 457.20M 283.60M 54.38M 49.09M 51.79M
Other cashflows from investing activities - 18.40M 36.88M 1.60M 1.60M
Dividends paid - - - - -
Change to inventory -211.60000M -116.90000M -85.03900M -54.90300M 9.14M
Change to account receivables 160.00M 150.20M 118.85M -402.09400M -36.05900M
Sale purchase of stock -7.20000M -74.30000M -103.43800M -47.88900M -10.72800M
Other cashflows from financing activities -43.80000M 2688.20M -77.02900M -48.04400M -48.77700M
Change to netincome - 106.20M 50.08M 12.28M 13.74M
Capital expenditures 209.30M 140.90M 292.72M 64.93M 27.23M
Change receivables - - 118.85M -402.09400M -36.05900M
Cash flows other operating - - -13.69900M -5.85600M 14.01M
Exchange rate changes - - - - 0.11M
Cash and cash equivalents changes - - 313.16M 436.16M 9.08M
Change in working capital -194.90000M -53.20000M -2.78000M -251.06800M -15.23900M
Stock based compensation 51.60M 48.40M 25.40M 21.02M 13.25M
Other non cash items -72.20000M 57.80M -0.04000M 20.65M 13.50M
Free cash flow 70.90M 744.40M 513.14M 564.84M 107.26M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
QDEL
Quidel Corporation		 -0.56 2.82% 19.30 - 15.41 0.94 0.56 1.76 8.68
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Quidel Corporation

9975 Summers Ridge Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Douglas C. Bryant Chairman & CEO 1958
Mr. Robert J. Bujarski J.D. Pres & COO 1969
Ms. Michelle A. Hodges Gen. Counsel 1960
Dr. Werner Kroll Ph.D. Sr. VP of R&D 1957
Mr. Joseph M. Busky CPA Chief Financial Officer 1968
Ms. Louise Brandy Chief Information Officer NA
Mr. Patrick E. Klein Chief Admin. Officer NA
Ruben Argueta Director of Investor Relations NA
Mr. Michael S. Iskra Chief Commercial Officer 1970
Phillip S. Askim VP, Associate Gen. Counsel & Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.